Alnylam Pharmaceuticals, Inc. (ALNY) vs Incyte Corporation (INCY)
- Alnylam Pharmaceuticals, Inc. ALNY 231.83 −0.94%
- Incyte Corporation INCY 112.95 −0.28%
Alnylam Pharmaceuticals, Inc. and Incyte Corporation are both Biotechnology companies. Alnylam Pharmaceuticals, Inc. is the larger, with a market value of $31.3B against $23.0B — 1.4× the size. Incyte Corporation trades at the lower P/E: 13.9× against 39.5×. Alnylam Pharmaceuticals, Inc. grew revenue faster over the last twelve months: 95.1% against 26.9%. Incyte Corporation has the higher net margin (27.7% vs 16.1%) and the higher return on invested capital (60.5% vs 0.00%). Across the 21 metrics below, Incyte Corporation leads on 17 and Alnylam Pharmaceuticals, Inc. on 4.
Valuation
Profitability
| Metric | ALNY | INCY | Biotechnology median |
|---|---|---|---|
| Gross margin | 79.65% | 92.62% | 65.16% |
| Operating margin | 20.81% | 30.56% | 0.00% |
| Net margin | 16.13% | 27.71% | 0.00% |
| Free cash flow margin | 17.07% | 32.48% | 0.00% |
| Return on equity | 96.55% | 30.67% | (56.36%) |
| Return on assets | 15.30% | 23.55% | (48.04%) |
| Return on invested capital | 0.00% | 60.50% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack